FDA shall submit
the final version of the guidance document to OMB using the change
worksheet (83-C).
Inventory as of this Action
Requested
Previously Approved
12/31/2007
12/31/2007
80
0
0
6,400
0
0
0
0
0
This guidance provides recommendations
to sponsors submitting or holding investigational new drug
applications (INDs), new drug applications (NDAs), or biologics
license applications (BLAs) on what pharmacogenomic data should be
submitted to the agency during the drug development process.
Sponsors holding and applicants submitting INDs, NDAs, or BLAs are
subject to FDA requirements for submitting to the agency data
relevant to drug safety and efficacy (SS 312.22, 312.23, 312.31,
312.33, 314.50, 314.81, 601.2, and 601.12).
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.